Lung Cancer News from the Largest Oncology Meeting

2019-06-17T12:07:14-05:00June 13th, 2019|Hot Topics, News|

The GO2 Science and Research team just returned from the 2019 American Society of Clinical Oncology (ASCO) meeting. We connect you and your loved ones to the latest research and treatment options by keeping up with the latest advances at meetings like ASCO. While there we saw exciting presentations on new research advances and potential new treatment options for lung cancer patients. Below are some key takeaways: Targeted Therapy Key Takeaway: All patients should receive comprehensive molecular testing/biomarker testing because [...]

Research Wins Big

2019-06-04T19:19:25-05:00May 7th, 2019|News|

The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care” – individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for [...]

2019 Forecast for Lung Cancer Research and Treatments

2019-01-24T16:10:01-05:00January 24th, 2019|Hot Topics|

Last year was an exciting year for lung cancer research with more U.S. Food and Drug Administration (FDA) approval decisions relevant to lung cancer than ever before.  So, what can we expect for 2019?  Another eventful year with researchers studying how to best give the approved drugs (i.e. what order and combinations) as well as expanding the options with more types of therapies. IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER First, there is the rapidly growing field of immunotherapy.  We have [...]

FDA Approves Targeted Therapy for Solid Tumors with NTRK Gene

2018-11-27T14:40:07-05:00November 27th, 2018|Hot Topics, News|

Tuesday, November 27, 2018 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with advanced solid tumors, including lung cancer, that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance mutation. These gene fusions can be in the NTRK1, NTRK2, or NTRK3 genes. Patients with advanced lung cancer who had NTRK gene fusions were included in the research that led to this [...]

FDA Approves Tagrisso as First-line Treatment for NSCLC

2018-04-23T13:55:25-05:00April 19th, 2018|Hot Topics, News|

Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa). Up until this point, Tagrisso was approved as a second-line treatment [...]